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Calogera M. Simonaro,* Jae-Ho Park,* Efrat Eliyahu, Nataly Shtraizent,
Margaret M. McGovern, and Edward H. Schuchman
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Acid sphingomyelinase (ASM) is the lipid hydrolase that is deficient in types A and B Niemann-Pick disease (NPD).
Here, we demonstrate that the gene encoding ASM (SMPD1) is paternally imprinted and that differential expression
of the mutant alleles in patients with ASM-deficient NPD and in carriers influences the disease phenotype. Com-
parison of the results of genomic sequencing versus reverse-transcriptase polymerase chain reaction sequencing for
several patients with NPD revealed preferential expression of one mutant allele. Further analysis of one family
showed that the expressed allele was maternally inherited and that the distinct clinical presentations of the individual
patients were correlated with the amount of residual ASM activity expressed from the maternal mutation. Treatment
of NPD cell lines with 5-aza-2′-deoxycytidine enhanced the expression of the paternal SMPD1 allele, and bisulfite
genomic sequencing identified which CpG dinucleotides within the SMPD1 promoter were methylated. In a related
set of studies, we identified a carrier individual who had ∼15% of normal ASM activity and clinical features of
ASM-deficient NPD. DNA sequencing confirmed that this individual carried a single SMPD1 mutation and that
this mutant allele was preferentially expressed. These data thus demonstrate, for the first time, imprinting at the
SMPD1 gene and reveal the influence of this epigenetic modification on the presentation of ASM-deficient NPD.
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Acid sphingomyelinase (ASM) is the lipid hydrolase that
is deficient in types A and B Niemann-Pick disease (NPD)
(MIMs 257200 and 607616, respectively).1 Individuals
with this disorder inherit two mutations in the SMPD1
gene (MIM 607608), which is located on the short arm
of chromosome 11 within a cluster of imprinted genes
(fig. 1).2 The clinical presentation of ASM-deficient NPD
is dependent, in large part, on the amount of residual
enzymatic activity expressed in various tissues from the
individual mutant alleles.1 Severe mutations lead to type
A NPD, an infantile form of the disease that follows a
uniform and rapid neurodegenerative course, leading to
death before age 4 years. Type B NPD, on the other
hand, is a very heterogeneous disorder that may present
in early childhood or adulthood, affects multiple organ
systems, and progresses at variable rates in different pa-
tients. The basis of this variability is poorly understood
and does not always correlate with the individual
SMPD1 mutations. In addition, some carrier individuals
for ASM-deficient NPD have features of the disease,
which is an unusual finding for an autosomal recessive
disorder such as this.3
In 2000, a patient with Beckwith-Wiedemann syn-
drome (BWS) was described who had ∼30% of normal
ASM activity in cultured skin fibroblasts.4 This 23-mo-
old child had a normal karyotype, which suggested uni-
parental disomy of paternal chromosome 11p15. Such
disomic events are responsible for ∼20% of all BWS
cases.5 An accompanying article from the same group
suggested that the SMPD1 gene might be imprinted, on
the basis of the reduced ASM activity in this patient, the
possibility of chromosome 11p15 uniparental disomy,
and the fact that the SMPD1 gene had structural features
common to other imprinted genes.6
To assess imprinting at the SMPD1 locus, we studied
several heteroallelic patients with ASM-deficient NPD.
All patients had a confirmed enzymatic diagnosis of
ASM-deficient NPD and voluntarily provided written
informed consent before participation in this study. Pa-
tient 1 was a 22-year-old white man who had presented
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Figure 1 Schematic representation of the imprinting cluster on the short arm of human chromosome 11, with the location of the SMPD1
gene shown. Paternally imprinted genes (black boxes), maternally imprinted genes (gray boxes), and genes exhibiting biallelic expression (white
boxes) are shown. The two BWS candidate regions (BWSCR1 and BWSCR2) are indicated. Only those human genes for which imprinting has
been confirmed are shown. cen p centromere; tel p telomere.
Figure 2 Expression pattern of SMPD1 mutant alleles in ASM-deficient NPD. A, Pedigree of the family with three affected members.
Patients 2 and 3 are adult siblings with mild ASM-deficient NPD. Patient 4, a paternally related cousin, is a child with severe ASM-deficient
NPD. Genotype analysis identified the shared paternal (C92W) and unique maternal (S248R and P184L) mutations. Symbols with a dot indicate
obligate carriers. Blackened symbols indicate affected individuals. B, Normal and mutant C92W alleles, distinguishable by restriction-enzyme
digestion with MwoI after RT-PCR amplification. The enzyme digested the amplified 239-bp fragment containing the wild-type (C92) maternal
sequence into a smaller 129-bp fragment. After digestion of radioactive RT-PCR products from each of the three patients and quantification
of the signal from the paternal (W92 mutant) and maternal (C92 wild-type) fragments, expression from the maternal allele was found to account
for ∼80% of the products. An unrelated, unaffected individual was included as a control. In this individual, both the maternal and the paternal
alleles had the normal C92 sequence; thus, only the lower band is evident. Lanes show PCR reactions with (“”) and without (“”) the cDNA
template. The numbers below each lane marked with a plus sign () indicate the percentages of paternal (top number) and maternal (bottom
number) alleles, as determined by densitometry and IMAGEQUANT software.
with NPD at age 18 mo. During childhood, he had re-
current otitis media infections, sinusitis, and pneumo-
nias, and he underwent a partial splenectomy at age 12
years. Neurological and fundoscopic examinations were
normal, although pulmonary function testing revealed a
diffusion capacity of 54% of the predicted value. Patient
1 also has the typical cholesterol abnormalities associ-
ated with ASM-deficient NPD. Patients 2 and 3 are adult
siblings who are first cousins of patient 4 and were iden-
tified after patient 4 received a diagnosis of ASM-defi-
cient NPD at age 1 year (see pedigree in fig. 2A). Patients
2 and 3 have a mild disease phenotype, with normal
neurological and ophthalmologic findings and mild he-
patosplenomegaly. Pulmonary function has remained es-
sentially normal in both patients. In contrast, patient 4
has severe ASM-deficient NPD and presented with he-
patosplenomegaly in early childhood, which led to bone
marrow transplantation at age 2 years.
As illustrated in figure 3, two distinct SMPD1 mu-
tations were readily identified in these patients after di-
rect sequencing of genomic DNA. However, sequencing
of RT-PCR products from the same individuals revealed
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Figure 3 Comparison of genomic sequencing (GE) versus RT-PCR sequencing (RT) in ASM-deficient NPD. Results of sequencing two
different cell lines (lymphoblasts and fibroblasts) from patient 1 are shown. This individual had two distinct genomic mutations caused by
nucleotide substitutions in exons 2 and 4 (CrG and CrT, respectively). When genomic sequencing was performed on either cell line, both
mutations were evident (arrows). Note that the signal intensities (peak heights) for the wild-type and mutant nucleotides were approximately
equivalent, which is consistent with heterozygosity of each mutation. However, when RNA was prepared from the same cell lines and the
reverse-transcribed cDNA products were sequenced, only one of the alleles was preferentially expressed (arrows). This preferentially expressed
allele carried the mutant nucleotide (G) in exon 2 and the wild-type nucleotide (C) in exon 4.
that one of the mutant alleles (in this case, the allele
expressing the mutant G in exon 2 and the wild-type C
in exon 4) was preferentially expressed.
To further evaluate preferential expression of the ma-
ternal or paternal SMPD1 alleles, we investigated the
family with the three NPD-affected individuals. As men-
tioned above, two of the members of this family (patients
2 and 3) were adult siblings with clinically mild NPD,
whereas the third (patient 4) was a paternally related
first cousin with severe NPD (fig. 2A). The shared pa-
ternal mutation in these patients was at codon 92 (W92)
and could be distinguished from the wild-type (maternal)
allele (C92) by restriction-enzyme digestion with MwoI,
which detects the CrG nucleotide change at nucleotide
position 276 of the full-length cDNA sequence.7 Figure
2B illustrates that, after semiquantitative RT-PCR and
restriction-enzyme analysis of each patient and an un-
related normal control individual, the maternal SMPD1
allele was found to be preferentially expressed, which is
consistent with paternal imprinting at this locus.
We next introduced the maternal (expressed) SMPD1
mutations found in these three patients (i.e., P184L for
patients 2 and 3, and S248R for patient 4) into the full-
length ASM cDNA and transiently expressed the mutant
constructs in COS-1 cells. The P184L mutation found
in the two adult patients with mild disease expressed
∼8% of normal ASM activity in COS-1 cells, whereas
the S248R mutation found in the child with severe dis-
ease expressed no residual ASM activity. Moreover, the
P184L mutation had been previously identified in several
unrelated patients with type B NPD and often has been
associated with a less severe form of the disorder.8 Thus,
the enzymatic activity produced from the expressed ma-
ternal allele in these patients correlated with the clinical
presentation of the disease.
To extend these observations, cultured lymphoblasts
from patients 2, 3, and 4 and a normal individual were
grown with and without the demethylating agent 5-aza-
2′-deoxycytidine (5Aza-dC) for 5–6 d. After 5Aza-dC
treatment of the lymphoblasts, the expression of the pa-
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Figure 4 Enhanced expression of the paternal SMPD1 gene after
5Aza-dC treatment. Cultured fibroblasts from a representative ASM-
deficient individual (patient 4) were grown for 5 d with (20 mM) and
without (0 mM) 5Aza-dC. In the presence of 5Aza-dC, expression of
the mutant (paternal) allele was enhanced, as shown. Lanes represent
amplification reactions with (“”) and without (“” [negative con-
trol]) the cDNA template. The numbers below the lanes marked with
a plus sign () indicate the percentages of mutant paternal (top num-
ber) and wild-type maternal (bottom number) alleles.
Figure 5 Methylated CpG dinucleotides in the SMPD1 pro-
moter, identified by bisulfite sequencing. Two fragments within the
putative SMPD1 promoter region were PCR amplified from cells
grown with and without 5Aza-dC, and the amplified fragments were
subjected to bisulfite sequencing. No methylated sites were found in
fragment 1, whereas six were found in fragment 2. A, Schematic de-
piction of the six CpG sites that were differentially methylated in
fragment 2. A total of 26 clones were sequenced from cells grown
without 5Aza-dC, and 23 clones from cells grown with 5Aza-dC.
Methylation patterns of the individual clones are shown, and the num-
ber of clones found with each pattern is indicated (1#, 5#, etc.).
Blackened circles represent methylated sites; unblackened circles rep-
resent unmethylated sites. B, Summary of bisulfite sequencing data for
the six methylated CpG sites in fragment 2. The number of clones
containing each of the methylated sites is shown for the two groups
of clones (26 from untreated cells [0 mM] and 23 from treated cells
[20 mM]). Note that 5Aza-dC treatment led to substantial demethyl-
ation of sites 1–4.
ternal allele was enhanced and became equivalent to that
of the maternal allele, as illustrated in figure 4 for patient
4. Before 5Aza-dC treatment, expression of the paternal
allele was ∼20% that of the maternal allele. These results
suggest that methylation was responsible for the reduced
expression of the SMPD1 paternal allele.
We next performed bisulfite genomic sequencing of
two PCR fragments derived from the wild-type SMPD1
promoter region before and after 5Aza-dC treatment.
Fragment 1 included nt 340 to 279, and fragment
2 included nt 889 to 316 (numbered in accordance
with Schuchman et al.9). Although none of the 55 CpG
dinucleotides in fragment 1 were methylated under any
conditions, fragment 2 contained six methylated CpG
sites, some of which were demethylated in the presence
of 5Aza-dC. Sixteen nonmethylated CpG sites were also
present in fragment 2. Figure 5 summarizes the meth-
ylation patterns of the relevant six CpG sites in patient
3. Each circle represents one of the six sites, and meth-
ylation is indicated by a blackened circle. For these stud-
ies, a PCR fragment containing the six sites was ampli-
fied from cells with and without 5Aza-dC treatment, and
the amplified fragments were subsequently subcloned
into a plasmid vector for bisulfite sequencing. A total of
26 clones from cells without 5Aza-dC treatment and 23
clones from cells with treatment were subjected to bi-
sulfite sequencing. The methylation pattern of individual
clones are schematically depicted in figure 5A, and the
data are summarized in figure 5B.
As can be seen, all CpG sites were methylated in only
1 (“1#”) of the 26 clones analyzed in the absence of
5Aza-dC treatment. In five clones (“5#”), sites 1–4 were
methylated; in another clone, sites 1, 2, 3, and 6 were
methylated; and so forth. The most common pattern
observed for these clones was methylation at sites 1, 2,
and 4 (in six clones). Of the six sites in this region that
were methylated, sites 1–4 were differentially modified
in the 23 clones from cells treated with 5Aza-dC. These
results suggest that methylation at one or all of these
four sites is likely to be responsible for the imprinting
observed at the SMPD1 locus.
As noted above, there have been previous reports de-
scribing individuals who carry a single SMPD1 mutation
and exhibit features of ASM-deficient NPD (e.g., the
report by Lee et al.3). This is an unusual finding for a
recessive disorder, and we therefore hypothesized that
some individuals who are carriers for ASM-deficient
NPD might exhibit features of the disease because of
inheritance of the mutant allele on the maternal (i.e.,
preferentially expressed) chromosome. To investigate
this hypothesis, we studied an individual (patient 5) who
had received the diagnosis of ASM-deficient NPD as a
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Figure 6 Comparison of genomic sequencing (GE) versus RT-
PCR sequencing (RT) in an ASM-deficient NPD heterozygote. Cul-
tured skin fibroblasts from a carrier individual (patient 5) were studied.
This individual had one genomic mutation due to deletion of a cytosine
(Del C), leading to a frameshift mutation (fsP330). As can be seen,
when direct genomic sequencing was performed, both the wild-type
and the mutant alleles were evident. Note the overlap of the sequencing
signals at the site of the deletion (arrows), consistent with a frameshift.
Sequencing reactions from both directions (sense and antisense) are
shown. In contrast to the genomic sequencing results, when the reverse-
transcribed cDNA products were sequenced from the same individual,
preferential expression of the mutant allele (containing five cytosines
instead of six) was found.
child (on the basis of splenomegaly, bone marrow foamy
cells, and recurrent pulmonary infections) but who was
found to have ∼15% of normal ASM activity in cultured
cells, which is more consistent with carrier status than
with patient status. As an adult, most of his NPD-related
symptoms had resolved, but, on reevaluation at age 42
years, he was found to have abnormal low-density li-
poprotein and high-density lipoprotein cholesterol, sple-
nomegaly, and several other features associated with
ASM deficiency.
Genomic DNA sequencing revealed the presence of a
single fsP330 mutation in this individual (fig. 6), which
is consistent with his Ashkenazi Jewish ancestry.10 No-
tably, RT-PCR sequencing demonstrated preferential ex-
pression of this mutant allele. Although the parents of
patient 5 were not available for study, we predict, on
the basis of our previous data, that the preferentially
expressed mutant allele was maternally inherited. No-
tably, this carrier individual has two children, one of
whom inherited the fsP330 mutation. However, no
NPD-related symptoms in this child have been described,
which is consistent with the fact that he inherited the
fsP330 mutation on his paternal (imprinted) chromo-
some. Also, ASM activity in cultured skin fibroblasts
from this child was ∼54% of normal, which was sig-
nificantly greater than that seen in the father and thus
consistent with preferential expression of the maternal
wild-type allele.
Thus, we have demonstrated paternal imprinting at
the SMPD1 gene and have revealed that the maternal
mutation has a predominant influence on the presen-
tation of ASM-deficient NPD. These findings may ex-
plain some of the clinical heterogeneity in this disorder.
For example, two heteroallelic individuals with the same
genotype may have distinct phenotypes, depending on
whether the severe mutation is inherited on the expressed
(maternal) chromosome or the imprinted (paternal)
chromosome. This observation may also explain why
some carrier individuals exhibit some features of NPD.3
For example, NPD carriers who inherit the wild-type
allele on their paternal chromosome (and thus prefer-
entially express the maternal mutant allele) may have
reduced ASM activity (i.e., less than the expected 50%)
and perhaps may develop clinical features of NPD. We
confirmed this hypothesis in one such carrier individual
(patient 5), who preferentially expressed a mutant allele
carrying a severe frameshift mutation. As mentioned
above, patient 5 had ∼15% of normal ASM activity and,
as a child, was diagnosed with NPD on the basis of
splenomegaly, bone marrow foamy cells, and recurrent
pulmonary infections.
Our findings may also provide insights into the patho-
genesis of BWS. As noted above, the basis for this work
was the identification of an individual with BWS who
had reduced ASM activity. Presumably, this reduced ac-
tivity was due to uniparental disomy of paternal chro-
mosome 11. In the future, it will be informative to study
other individuals with BWS who have confirmed uni-
parental disomy of paternal chromosome 11p15 (∼20%
of all cases) and to examine their ASM levels. In addi-
tion, the status of the SMPD1 gene should be examined
in individuals with BWS who have other types of re-
arrangements involving the short arm of chromosome
11. Indeed, because ASM is involved in regulating cell
growth through the ceramide-mediated signaling path-
way,11,12 reduced activity of this enzyme may contribute
to the overgrowth and embryonic tumors associated
with this disorder.
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